"Pacritinib Bests BAT, Doesn’t Seem To Affect Survival"
Final results from the PERSIST-2 trial suggest pacritinib can be more effective than best available therapy (BAT) for patients with myelofibrosis and thrombocytopenia, and the drug has no significant effect on survival. “Pacritinib was shown to reduce both spleen volume and total symptom score, two very important clinical measures in myelofibrosis patients with thrombocytopenia, including those patients who received prior treatment with ruxolitinib,” said study author, John O. Mascarenhas, MD, associate professor of medicine, hematology and medical oncology, and director of the adult leukemia program at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai.
- John O. Mascarenhas, MD, Associate Professor, Medicine, Hematology and Medical Oncology, Director, Adult Leukemia Program, Leader, Clinical Investigation within Myeloproliferative Disorders Program, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
Additional coverage
Medscape
Rare Disease Report